19 documents

Read All
19:38 , Apr 27, 2018 |  BC Week In Review  |  Company News

Tonghua gets rights to two insulin products from Adocia

Adocia S.A. (Euronext:ADOC) granted Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) exclusive rights to develop and commercialize BioChaperone Lispro (BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia will receive...
Read More
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, double-dummy, 3-way crossover, German Phase Ib trial of subcutaneous BioChaperone Combo given before a meal on 3 consecutive days in 36 patients. The trial will compare BioChaperone Combo vs. subcutaneous ...
Read More
07:00 , Aug 26, 2016 |  BC Extra  |  Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks...
Read More
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

BioChaperone insulin: Phase I/II started

Adocia began a double-blind, 3-period crossover Phase I/II trial to compare single doses of HinsBet U100 vs. Humalog and Humulin given immediately prior to ingesting a standardized mixed meal in 36 Type I diabetics. Adocia...
Read More
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, crossover, German Phase Ib trial to compare 0.8 IU/kg Biochaperone Combo to 0.8 IU/kg Humalog Mix25 and 0.2 IU/kg Humalog insulin lispro plus 0.6 IU/kg Lantus insulin glargine in...
Read More
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, crossover, German Phase Ib trial to compare BioChaperone Combo to Humalog Mix25 given at the beginning of a standardized mixed meal in about 28 patients. In 2013, Adocia and Eli...
Read More
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

HinsBet BioChaperone insulin: Phase IIa data

A double-blind, crossover Phase IIa trial in 36 Type I diabetics showed that a single 0.2 U/kg dose of HinsBet met the primary endpoint of improving the rate of early insulin exposure vs. a single...
Read More
02:08 , Feb 7, 2015 |  BC Extra  |  Clinical News

Adocia climbs on fast-acting insulin data

Adocia S.A. (Euronext:ADOC) rose EUR 9.62 (15%) to EUR 73.40 after the company's HinsBet fast-acting insulin met the primary endpoint of an increase in recombinant human insulin bioavailability during the first hour after dosing compared...
Read More
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Final Phase I/II data

Final data from a double-blind, crossover, German Phase I/II trial in 20 Type I diabetics showed that a single 0.8 IU/kg dose of BioChaperone Combo had a faster onset of action, defined as time to...
Read More
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Anika Therapeutics Inc. (NASDAQ:ANIK) rose $11.43 (33%) to $45.90 on Wednesday after saying FDA approved Monovisc to treat osteoarthritis of the knee. Monovisc is a single injection that delivers hyaluronic acid from a non-animal...
Read More